Fas C-Terminal Tripeptide Mechanistic Insights, Clinical App

Fas C-Terminal Tripeptide: Mechanistic Insights, Clinical Applications, and Future Directions in Apoptosis Research

Introduction
Fas C-Terminal Tripeptide is a synthetic peptide derivative corresponding to the C-terminal tripeptide sequence of the Fas receptor (CD95/APO-1), a member of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor is a pivotal mediator of apoptosis, or programmed cell death, through its interaction with Fas ligand (FasL). Upon ligand binding, Fas undergoes trimerization and recruits adaptor proteins, leading to the formation of the death-inducing signaling complex (DISC) and subsequent activation of caspase cascades (Krammer, 2000, Cell Death Differ). The Fas C-Terminal Tripeptide functions as a selective inhibitor of Fas-mediated apoptosis by interfering with the recruitment of downstream signaling molecules, thereby modulating cell death pathways.

Mechanistically, the Fas C-Terminal Tripeptide is designed to mimic the terminal amino acid sequence of the Fas receptor’s cytoplasmic domain. This region is critical for the interaction with Fas-associated death domain protein (FADD) and subsequent caspase-8 activation (Peter & Krammer, 2003, Cell Death Differ). By competitively binding to FADD or disrupting the conformational integrity of the death domain, the tripeptide inhibits the assembly of DISC, thus preventing the initiation of apoptosis. This property renders the Fas C-Terminal Tripeptide a valuable research tool for dissecting apoptotic pathways and exploring therapeutic interventions in diseases characterized by aberrant apoptosis.

[Related: MRTX-1133] Clinical Value and Applications
The clinical value of the Fas C-Terminal Tripeptide lies primarily in its ability to modulate apoptosis, a process implicated in a wide spectrum of pathological conditions. Excessive or inappropriate activation of Fas-mediated apoptosis contributes to tissue damage in autoimmune diseases (e.g., systemic lupus erythematosus), neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), and ischemia-reperfusion injuries (Nagata, 1997, Cell). Conversely, resistance to Fas-induced apoptosis is a hallmark of many malignancies, enabling tumor cells to evade immune surveillance and therapeutic interventions (Owen-Schaub et al., 1994, Science).

Preclinical studies have demonstrated that the Fas C-Terminal Tripeptide can attenuate Fas-mediated cell death in models of hepatic injury, myocardial infarction, and neurodegeneration (Yin et al., 1999, J Exp Med; Feldenberg et al., 1999, Am J Physiol). In these contexts, administration of the tripeptide reduced tissue damage, preserved organ function, and improved survival outcomes. Furthermore, the peptide serves as a molecular probe for elucidating the role of Fas signaling in immune cell homeostasis, T-cell activation, and the pathogenesis of graft-versus-host disease (GVHD) (Wajant et al., 2003, Cell Death Differ).

[Related: PAOPA] In oncology research, the Fas C-Terminal Tripeptide is employed to investigate mechanisms of apoptosis resistance in cancer cells and to evaluate combinatorial strategies that sensitize tumors to Fas-mediated killing. Its application extends to drug screening platforms, where it aids in distinguishing Fas-dependent from Fas-independent cytotoxic effects of novel compounds.

Key Challenges and Pain Points Addressed
Current therapeutic approaches targeting apoptosis often lack specificity, resulting in off-target effects and unintended cytotoxicity. Small molecule inhibitors of caspases or pan-apoptotic agents can disrupt essential physiological processes, leading to immunosuppression, hepatotoxicity, or neurotoxicity (Riedl & Shi, 2004, Nat Rev Mol Cell Biol). The Fas C-Terminal Tripeptide addresses these challenges by offering a targeted means of modulating a discrete apoptotic pathway.

[Related: tcep hydrochloride] A major pain point in apoptosis research is the difficulty in dissecting the contribution of individual signaling components within complex cell death networks. The Fas C-Terminal Tripeptide, by specifically interfering with Fas-FADD interactions, enables researchers to delineate the role of Fas signaling in various cellular contexts without globally inhibiting apoptosis. This selectivity is particularly valuable in studies aiming to preserve beneficial apoptotic responses (e.g., elimination of autoreactive lymphocytes) while mitigating pathological cell loss.

Additionally, the tripeptide provides a tool for overcoming the limitations of genetic knockout models, which may be confounded by compensatory mechanisms or developmental defects. Its reversible, dose-dependent effects facilitate temporal control over Fas signaling, allowing for precise experimental manipulation.

Literature Review
A substantial body of literature supports the utility of Fas C-Terminal Tripeptide and related peptides in apoptosis research and therapeutic development:

1. **Yin et al. (1999, J Exp Med)** demonstrated that a synthetic Fas C-terminal peptide inhibited Fas-mediated hepatocyte apoptosis in vivo, reducing liver injury and mortality in a murine model of fulminant hepatitis.
2. **Feldenberg et al. (1999, Am J Physiol)** reported that the tripeptide protected renal tubular epithelial cells from Fas-induced apoptosis, suggesting potential applications in acute kidney injury.
3. **Peter & Krammer (2003, Cell Death Differ)** provided a comprehensive review of Fas signaling mechanisms, highlighting the critical role of the C-terminal domain in DISC assembly and apoptotic execution.
4. **Wajant et al. (2003, Cell Death Differ)** discussed the therapeutic implications of modulating Fas/FasL interactions in autoimmune and inflammatory diseases.
5. **Nagata (1997, Cell)** elucidated the molecular basis of Fas-mediated apoptosis and its relevance to immune regulation and disease pathogenesis.
6. **Owen-Schaub et al. (1994, Science)** identified defects in Fas signaling as a mechanism of immune evasion in cancer, underscoring the importance of pathway-specific modulators.
7. **Riedl & Shi (2004, Nat Rev Mol Cell Biol)** reviewed the structural biology of caspases and apoptotic regulators, emphasizing the need for selective inhibitors in therapeutic applications.

Collectively, these studies establish the Fas C-Terminal Tripeptide as a potent and selective inhibitor of Fas-mediated apoptosis, with broad utility in experimental and translational research.

Experimental Data and Results
Experimental investigations into the efficacy of Fas C-Terminal Tripeptide have employed both in vitro and in vivo models. In hepatocyte cultures, pre-treatment with the tripeptide significantly reduced FasL-induced caspase-8 activation, DNA fragmentation, and cell death, as measured by TUNEL assay and flow cytometry (Yin et al., 1999, J Exp Med). Dose-response analyses revealed that micromolar concentrations of the peptide achieved up to 80% inhibition of apoptosis without affecting cell viability under basal conditions.

In murine models of fulminant hepatitis, systemic administration of the tripeptide prior to Fas agonist challenge resulted in a marked decrease in serum transaminase levels, histological evidence of hepatocellular necrosis, and overall mortality. Similar protective effects were observed in models of renal ischemia-reperfusion injury, where the peptide preserved tubular architecture and reduced inflammatory infiltration (Feldenberg et al., 1999, Am J Physiol).

Mechanistic studies employing immunoprecipitation and Western blotting confirmed that the tripeptide disrupted the recruitment of FADD and procaspase-8 to the Fas receptor, thereby blocking DISC formation. Importantly, the peptide did not interfere with other death receptor pathways (e.g., TNF-R1), attesting to its specificity.

In cancer cell lines, the Fas C-Terminal Tripeptide was shown to restore sensitivity to chemotherapeutic agents by modulating apoptotic thresholds, suggesting potential utility in overcoming drug resistance (Owen-Schaub et al., 1994, Science). However, its effects were context-dependent, underscoring the need for careful experimental design.

Usage Guidelines and Best Practices
For experimental applications, the Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder and should be reconstituted in sterile, endotoxin-free water or appropriate buffer to a stock concentration (e.g., 1-10 mM). Working concentrations in cell culture assays generally range from 1 to 100 μM, depending on cell type and experimental objectives. It is recommended to perform preliminary dose-response and time-course studies to optimize conditions for each system.

The peptide should be added to culture media 30-60 minutes prior to FasL or agonistic antibody stimulation to ensure adequate cellular uptake and target engagement. For in vivo studies, dosing regimens should be guided by published protocols and adjusted for species, route of administration (e.g., intravenous, intraperitoneal), and disease model. Pharmacokinetic and toxicity assessments are advised to determine optimal dosing intervals and minimize off-target effects.

Proper controls, including vehicle-treated and scrambled peptide groups, are essential for interpreting results. Researchers should also monitor for potential interference with unrelated signaling pathways and verify specificity using complementary genetic or pharmacological approaches.

Future Research Directions
Despite its demonstrated utility, several avenues remain for further exploration of the Fas C-Terminal Tripe Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688